ArticleJournal of market access & health policy2017
Filling the gap in CNS drug development: evaluation of the role of drug repurposing.
Article in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Memantine Confers Multi-Target Protection in a Zebrafish Seizure Model: Attenuating Epileptic Behavior, GluN2A Overexpression, and Oxidative Stress.Journal of neurochemistry · 2026Article
- A Novel Integrative Framework for Depression: Combining Network Pharmacology, Artificial Intelligence, and Multi-Omics with a Focus on the Microbiota-Gut-Brain Axis.Current issues in molecular biology · 2025Review
- Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation.Neurology · 2025Observational
- Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings.Cells · 2024Review
- Advancements in Drug Repurposing: Examples in Psychiatric Medications.International journal of molecular sciences · 2023Article
- Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders.Pharmaceutics · 2022Review
- Novel Molecular Targets of Antidepressants.Molecules (Basel, Switzerland) · 2022Review
- GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.International journal of molecular sciences · 2021Review
- Drug Repurposing for the Management of Depression: Where Do We Stand Currently?Life (Basel, Switzerland) · 2021Review
- Drug Repurposing for Rare Diseases: A Role for Academia.Frontiers in pharmacology · 2021Article
- Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.Current pharmaceutical design · 2020Review
- Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review.Frontiers in neuroscience · 2019Review
- The Role of Precision Medicine in Child Psychiatry: What Can We Expect and When?Journal of the American Academy of Child and Adolescent Psychiatry · 2018Article
- Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1α Stabilization.Molecular neurobiology · 2018Article
- Immune-based strategies for mood disorders: facts and challenges.Expert review of neurotherapeutics · 2018Review
- The promise and challenges of drug repurposing in psychiatry.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory.Frontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.